These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 26867766)

  • 1. iRGD-targeted delivery of a pro-apoptotic peptide activated by cathepsin B inhibits tumor growth and metastasis in mice.
    Qifan W; Fen N; Ying X; Xinwei F; Jun D; Ge Z
    Tumour Biol; 2016 Aug; 37(8):10643-52. PubMed ID: 26867766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-penetrating peptide fused to a pro-apoptotic peptide facilitates effective gastric cancer therapy.
    Huang Y; Li X; Sha H; Zhang L; Bian X; Han X; Liu B
    Oncol Rep; 2017 Apr; 37(4):2063-2070. PubMed ID: 28260064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-administration of kla-TAT peptide and iRGD to enhance the permeability on A549 3D multiple sphere cells and accumulation on xenograft mice.
    Hu C; Chen X; Huang Y; Chen Y
    Chem Biol Drug Des; 2018 Aug; 92(2):1567-1575. PubMed ID: 29722179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bladder tumor-targeted delivery of pro-apoptotic peptide for cancer therapy.
    Jung HK; Kim S; Park RW; Park JY; Kim IS; Lee B
    J Control Release; 2016 Aug; 235():259-267. PubMed ID: 27282414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-penetrating iRGD peptide inhibits metastasis.
    Sugahara KN; Braun GB; de Mendoza TH; Kotamraju VR; French RP; Lowy AM; Teesalu T; Ruoslahti E
    Mol Cancer Ther; 2015 Jan; 14(1):120-8. PubMed ID: 25392370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-Administration Of iRGD Enhances Tumor-Targeted Delivery And Anti-Tumor Effects Of Paclitaxel-Loaded PLGA Nanoparticles For Colorectal Cancer Treatment.
    Zhong Y; Su T; Shi Q; Feng Y; Tao Z; Huang Q; Li L; Hu L; Li S; Tan H; Liu S; Yang H
    Int J Nanomedicine; 2019; 14():8543-8560. PubMed ID: 31802868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theranostic iRGD peptide containing cisplatin prodrug: Dual-cargo tumor penetration for improved imaging and therapy.
    Cho HJ; Park SJ; Lee YS; Kim S
    J Control Release; 2019 Apr; 300():73-80. PubMed ID: 30831135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes.
    Simón-Gracia L; Hunt H; Scodeller P; Gaitzsch J; Kotamraju VR; Sugahara KN; Tammik O; Ruoslahti E; Battaglia G; Teesalu T
    Biomaterials; 2016 Oct; 104():247-57. PubMed ID: 27472162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy.
    Sha H; Zou Z; Xin K; Bian X; Cai X; Lu W; Chen J; Chen G; Huang L; Blair AM; Cao P; Liu B
    J Control Release; 2015 Feb; 200():188-200. PubMed ID: 25553823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor targeting and microenvironment-responsive multifunctional fusion protein for pro-apoptotic peptide delivery.
    Yin J; Liu D; Bao L; Wang Q; Chen Y; Hou S; Yue Y; Yao W; Gao X
    Cancer Lett; 2019 Jun; 452():38-50. PubMed ID: 30904618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced anticancer efficacy of paclitaxel through multistage tumor-targeting liposomes modified with RGD and KLA peptides.
    Sun J; Jiang L; Lin Y; Gerhard EM; Jiang X; Li L; Yang J; Gu Z
    Int J Nanomedicine; 2017; 12():1517-1537. PubMed ID: 28280323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inducing Optimal Antitumor Immune Response through Coadministering iRGD with Pirarubicin Loaded Nanostructured Lipid Carriers for Breast Cancer Therapy.
    Deng C; Jia M; Wei G; Tan T; Fu Y; Gao H; Sun X; Zhang Q; Gong T; Zhang Z
    Mol Pharm; 2017 Jan; 14(1):296-309. PubMed ID: 27936775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.
    Yu KF; Zhang WQ; Luo LM; Song P; Li D; Du R; Ren W; Huang D; Lu WL; Zhang X; Zhang Q
    Int J Nanomedicine; 2013; 8():2473-85. PubMed ID: 23885174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. iRGD-conjugated DSPE-PEG2000 nanomicelles for targeted delivery of salinomycin for treatment of both liver cancer cells and cancer stem cells.
    Mao X; Liu J; Gong Z; Zhang H; Lu Y; Zou H; Yu Y; Chen Y; Sun Z; Li W; Li B; Gao J; Zhong Y
    Nanomedicine (Lond); 2015; 10(17):2677-95. PubMed ID: 26355733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation.
    Hu C; Huang Y; Chen Y
    Mol Pharm; 2019 Feb; 16(2):561-572. PubMed ID: 30592418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis.
    Sugahara KN; Scodeller P; Braun GB; de Mendoza TH; Yamazaki CM; Kluger MD; Kitayama J; Alvarez E; Howell SB; Teesalu T; Ruoslahti E; Lowy AM
    J Control Release; 2015 Aug; 212():59-69. PubMed ID: 26071630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. iRGD-Guided Silica/Gold Nanoparticles for Efficient Tumor-Targeting and Enhancing Antitumor Efficacy Against Breast Cancer.
    Hou X; Chen Q; Fang Y; Zhang L; Huang S; Xu M; Ren Y; Shi Z; Wei Y; Li L
    Int J Nanomedicine; 2024; 19():8237-8251. PubMed ID: 39157735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A surface charge-switchable and folate modified system for co-delivery of proapoptosis peptide and p53 plasmid in cancer therapy.
    Chen S; Rong L; Lei Q; Cao PX; Qin SY; Zheng DW; Jia HZ; Zhu JY; Cheng SX; Zhuo RX; Zhang XZ
    Biomaterials; 2016 Jan; 77():149-63. PubMed ID: 26599622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell penetrating peptides improve tumor delivery of cargos through neuropilin-1-dependent extravasation.
    Kadonosono T; Yamano A; Goto T; Tsubaki T; Niibori M; Kuchimaru T; Kizaka-Kondoh S
    J Control Release; 2015 Mar; 201():14-21. PubMed ID: 25592386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of a proapoptotic peptide to intratumorally spreading cancer therapy.
    Chen R; Braun GB; Luo X; Sugahara KN; Teesalu T; Ruoslahti E
    Cancer Res; 2013 Feb; 73(4):1352-61. PubMed ID: 23248118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.